German price of Pepaxti published
Oncopeptides recently successfully agreed on a reimbursed price for Pepaxti in Germany that in the company’s view reflects the innovation of the drug and is in line with the company’s financial projections.
The updated list price for one dose of Pepaxti in Germany is now €7,058 per month (€3,529 per vial). The previous list price was €10,900 (€5,450 per vial). Oncopeptides has accrued for a discounted price in line with the now confirmed price since April 1. It is common procedure to receive a lower price following negotiations in different markets, and the price received in Germany is in line with the company´s expectations.
For more information, you may also watch the September 28 episode of Oncopeptalks, where Sofia Heigis explains the pricing process and her view on the German price negotiations.
Why are you communicating this now?
As previously communicated, Oncopeptides has decided to communicate the final price in Germany once it becomes public information through the publication in Lauer Taxe, a database of all pharmaceuticals approved on the German market. This to not disturb ongoing price negotiations in other markets.
What price have you used this far when selling in Germany?
We have a current list price of €10,900 per month (€5,450 per vial), however we have accrued for a discounted price in line with the now confirmed price since April 1. It is common procedure to receive a lower price following negotiations in different markets.
How are price negotiations in Germany conducted?
After a drug receives marketing approval from the European Medicines Agency (EMA), individual European Union member states decide the pricing and reimbursement of that drug within their legislation. In Germany, this is an established system of additional benefit evaluation (AMNOG) and reimbursed price negotiation based on the AMNOG rating.
How can the negotiated price in Germany affect price negotiations in other EU markets?
The price of a drug negotiated in Germany can influence its pricing in other European countries due to External Price Referencing (EPR), where countries compare drug prices with those in other markets. Given Germany’s status as a key reference country in many EPR systems, a price change there can set a benchmark for other nations. However, individual countries also weigh other factors like health system priorities and economic conditions when setting drug prices.